Lung Cancer | Specialty

IPI/NIVO in Metastatic NSCLC

June 28th 2018

Chemotherapy With I-O Therapy in EGFR- or ALK-Mutated NSCLC

June 28th 2018

Metastatic NSCLC: A Look at the IMpower150 Trial

June 28th 2018

Pembrolizumab: Monotherapy Versus Combination Therapy

June 28th 2018

Pembrolizumab and Chemotherapy in Advanced NSCLC

June 28th 2018

Implications for Pembrolizumab in NSCLC

June 28th 2018

Dr. Pennell on the Economic Impact of Next-Generation Sequencing

June 27th 2018

Nathan Pennell, MD, PhD, director, Lung Cancer Medical Oncology Program, Cleveland Clinic Taussig Cancer Institute, discusses the economic impact of next-generation sequencing.

Atezolizumab Combo Improves Survival in Frontline SCLC

June 25th 2018

Combining frontline atezolizumab with chemotherapy improved overall survival and progression-free survival compared with chemotherapy alone in patients with extensive-stage small cell lung cancer.

Expert Discusses Potential Breakthroughs in ROS1+ and BRAF+ NSCLC

June 25th 2018

Sai-Hong Ignatius Ou, MD, PhD, discusses the current landscapes of ROS1-positive and BRAF-mutant non–small cell lung cancer.

FDA Accepts Application for Frontline Nivolumab/Ipilimumab in TMB-High NSCLC

June 22nd 2018

The FDA has accepted a supplemental biologics license application for the combination of nivolumab plus ipilimumab for the frontline treatment of patients with advanced non–small cell lung cancer with tumor mutational burden ≥10 mutations per megabase.

Dr. Husain on Plasma-Based Testing in Lung Cancer

June 20th 2018

Hatim Husain, MD, assistant professor of Medicine, Moores Cancer Center, University of California, San Diego, discusses plasma-based testing in lung cancer.

The ALK Story: Rapid Bench-to-Bedside Journey Helps Set New Pace for Cancer Drugs

June 15th 2018

Alice T. Shaw, MD, PhD, and D. Ross Camidge, MD, PhD, discuss the evolution of ALK-targeting therapies, the impact on the drug development paradigm, and the prospects for future advancements.

Dr. Borghaei Discusses the Results of CheckMate-227 in NSCLC

June 14th 2018

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the results of the CheckMate-227 trial in non–small cell lung cancer.

Patients Aged

June 13th 2018

Patients younger than 65 years experienced net cancer costs that were higher for breast, colorectal, lung, and prostate cancer compared with patients who were 65 years and older.

Frontline Osimertinib Approved in Europe for EGFR-mutant NSCLC

June 11th 2018

The European Commission has approved osimertinib (Tagrisso) as a frontline treatment for patients with EGFR-mutant locally-advanced or metastatic non–small cell lung cancer.

Dr. Ramalingam on Plasma EGFR Mutations as a Predictor of Response in NSCLC

June 9th 2018

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses plasma EGFR mutations as a predictor of response to osimertinib (Tagrisso) in the AURA3 trial in non–small cell lung cancer.

Expert Says Paradigm Shift Imminent in SCLC

June 7th 2018

Anne Chiang, MD, PhD, discusses recent developments with immunotherapy and the overall outlook for the treatment landscape of small cell lung cancer.

Nivolumab Plus Low-Dose Ipilimumab Shows Durable Responses for PD-L1-Negative, TMB-High NSCLC

June 6th 2018

The combination of nivolumab and low-dose ipilimumab reduced the risk of progression or death by 52% compared with standard platinum doublet chemotherapy for patients with metastatic PD-L1–negative, tumor mutation burden-high non–small cell lung cancer.

Adding Bevacizumab to Erlotinib Prolongs PFS in EGFR-Mutated NSCLC

June 6th 2018

The combination of bevacizumab (Avastin) and erlotinib (Tarceva) is superior to erlotinib alone as upfront treatment for non–small cell lung cancer harboring EGFR mutations.

Frontline Atezolizumab Regimen Improves Survival for NSCLC

June 5th 2018

The combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel educed the risk of death by 22% compared with bevacizumab and chemotherapy in patients with advanced wild-type non-squamous non–small cell lung cancer.